Atlas Trials

Blue Earth Diagnostics

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Blue Earth Diagnostics

RecordFirmDate
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications (NCT07702292)Blue Earth Diagnostics2026-06-30
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence (NCT07569926)Blue Earth Diagnostics2026-06-01
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications (NCT07432633)Blue Earth Diagnostics2026-02-19
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (NCT06604442)Blue Earth Diagnostics2024-12-04
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (NCT04410133)Blue Earth Diagnostics2020-10-26
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) (NCT04410367)Blue Earth Diagnostics2020-08-31
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence (NCT04186845)Blue Earth Diagnostics2020-05-04
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer. (NCT04186819)Blue Earth Diagnostics2020-03-02
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer (NCT03995888)Blue Earth Diagnostics2019-06-11

Track Blue Earth Diagnostics automatically

Every clearance here is in the API, with alerts when new ones post.